Stadienadaptierte therapie des mammakarzinoms

In Germany more than 50,000 women are newly diagnosed with breast cancer each year of whom 19,000 die. The mortality is decreasing probably because of better and more consequent adjuvant and metastatic treatment rather than increasing incidence. The following article demonstrates that not only the stage of breast cancer but also prognostic and predictive factors, like hormone (estrogen, progesterone) receptor status and the her-2/ neu status, are of the utmost importance when deciding on the adjuvant and metastatic treatment. Neoadjuvant treatment should be considered if all information is available at the time of diagnosis before surgery and the decision on the adjuvant treatment can be made at that time point. Local therapy, such as surgery and radiation are absolutely necessary in the treatment of primary breast cancer. In advanced and metastatic breast cancer the pre-treatment and palliative targets are the main factors which have to be considered.